(Finance) – The British pharmaceutical company GSK announced that it had entered into an agreement under which will acquire Aiolos Bioa clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of patients with certain respiratory and inflammatory conditions, for a upfront payment of $1 billion And up to $400 million in certain payments success-based regulators.
The acquisition provides GSK withaccess to AIO-001 of Aiolos, a potentially best-in-class, long-acting, anti-thymic lymphopoietin stromal (TSLP) monoclonal antibody ready to enter Phase II clinical development for the treatment of adult patients with asthma, with potential for further indications including chronic rhinosinusitis with nasal polyps. AIO-001 has been exclusively licensed to Aiolos outside of China by Jiangsu Hengrui Pharmaceuticals.